Antiviral drug

Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

Retrieved on: 
Wednesday, May 12, 2021
HIV/AIDS, Hepatotoxins, Medical specialties, Retroviridae, Management of HIV/AIDS, HIV, Antiviral drug, Zidovudine, HIV/AIDS research

Presentation can be found at https://www.enochianbio.com/about-us/collaborations/\nA 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.

Key Points: 
  • Presentation can be found at https://www.enochianbio.com/about-us/collaborations/\nA 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.
  • The NK and GDT cells were collected from a person who does not have HIV.
  • This could potentially allow persons living with HIV to stop antiviral treatment for extended periods of time.
  • There is no assurance the findings will result in an effective alternative treatment for HIV.

Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

Retrieved on: 
Wednesday, May 12, 2021
HIV/AIDS, Hepatotoxins, Medical specialties, Retroviridae, Management of HIV/AIDS, HIV, Antiviral drug, Zidovudine, HIV/AIDS research

Presentation can be found at https://www.enochianbio.com/about-us/collaborations/\nA 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.

Key Points: 
  • Presentation can be found at https://www.enochianbio.com/about-us/collaborations/\nA 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.
  • The NK and GDT cells were collected from a person who does not have HIV.
  • This could potentially allow persons living with HIV to stop antiviral treatment for extended periods of time.
  • There is no assurance the findings will result in an effective alternative treatment for HIV.

Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board

Retrieved on: 
Wednesday, May 5, 2021
Branches of biology, Life sciences, Biology, Genetic engineering, Applied genetics, Medical genetics, Biotechnology, Bioethics, Gene therapy, Therapy, AAV, Antiviral drug

b'SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (\xe2\x80\x9cExcision\xe2\x80\x9d), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of gene therapy and rare disease expert, Nicole Paulk, Ph.D., to its Scientific Advisory Board (SAB).\n\xe2\x80\x9cWe would like to give a warm welcome to gene therapy pioneer Dr. Nicole Paulk as our newest SAB member.

Key Points: 
  • b'SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (\xe2\x80\x9cExcision\xe2\x80\x9d), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of gene therapy and rare disease expert, Nicole Paulk, Ph.D., to its Scientific Advisory Board (SAB).\n\xe2\x80\x9cWe would like to give a warm welcome to gene therapy pioneer Dr. Nicole Paulk as our newest SAB member.
  • \xe2\x80\x9cAs one of the world\xe2\x80\x99s preeminent experts in viral gene therapy, Nicole has already made substantial contributions to Excision\xe2\x80\x99s programs targeting HIV, Hepatitis B and Herpes Virus.\xe2\x80\x9d\nDr.
  • Paulk is an Assistant Professor of AAV Gene Therapy at the University of California San Francisco (UCSF) Dept.
  • of Pediatrics, where she developed enabling technologies in host-virus interactions, AAV gene therapy, and preclinical therapeutic development.

HeiQ launches high-tech mask featuring ground-breaking copper technology shown to deactivate the COVID-19 virus in five minutes

Retrieved on: 
Wednesday, May 5, 2021
Health, Medicine, Biocides, Antiviral drug, Surgical mask, Antifungal, Copper, Virus, Antibiotic, Bacteria

HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.

Key Points: 
  • HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.
  • The antiviral, antibacterial and antifungal properties of copper have been known for centuries and have been demonstrated by many laboratory studies.
  • HeiQ MetalliX treated materials release copper ions which deactivate viruses and bacteria.
  • Further, it gives an edgy look, making it an improved alternative to surgical masks in many ways," says Carlo Centonze, co-founder and CEO of HeiQ Group.\n'

HeiQ launches high-tech mask featuring ground-breaking copper technology shown to deactivate the COVID-19 virus in five minutes

Retrieved on: 
Wednesday, May 5, 2021
Health, Medicine, Biocides, Antiviral drug, Surgical mask, Antifungal, Copper, Virus, Antibiotic, Bacteria

HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.

Key Points: 
  • HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.
  • The antiviral, antibacterial and antifungal properties of copper have been known for centuries and have been demonstrated by many laboratory studies.
  • HeiQ MetalliX treated materials release copper ions which deactivate viruses and bacteria.
  • Further, it gives an edgy look, making it an improved alternative to surgical masks in many ways," says Carlo Centonze, co-founder and CEO of HeiQ Group.\n'

Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum

Retrieved on: 
Monday, May 3, 2021
Sexually transmitted diseases and infections, Molluscum contagiosum, Poxviruses, Antiviral drug, Medical specialties

b'DURHAM, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (\xe2\x80\x9cthe Company\xe2\x80\x9d or \xe2\x80\x9cNovan\xe2\x80\x9d) (Nasdaq: NOVN), today announced the final patient has completed their last Week-12 visit in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum (\xe2\x80\x9cmolluscum\xe2\x80\x9d).

Key Points: 
  • b'DURHAM, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (\xe2\x80\x9cthe Company\xe2\x80\x9d or \xe2\x80\x9cNovan\xe2\x80\x9d) (Nasdaq: NOVN), today announced the final patient has completed their last Week-12 visit in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum (\xe2\x80\x9cmolluscum\xe2\x80\x9d).
  • We remain focused on executing our remaining steps according to plan and reporting topline efficacy and safety data in June.
  • Our product candidate, SB206, represents a promising opportunity to provide patients with treatment benefit and address the unmet needs in the treatment landscape for molluscum.
  • The Company\xe2\x80\x99s lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study.

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis--Phase 2 Interim Analysis Results from RUBY Clinical Trial

Retrieved on: 
Thursday, April 29, 2021
Health sciences, Health, Conjunctivitis, Measles, Adenoviridae, OKG, Antiviral drug, Clinical trial

b"San Diego, California and Melbourne, Australia--(Newsfile Corp. - April 29, 2021) - Okogen, a clinical-stage specialty ophthalmic biotechnology company announced the interim analysis results from RUBY, the company's Phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis.

Key Points: 
  • b"San Diego, California and Melbourne, Australia--(Newsfile Corp. - April 29, 2021) - Okogen, a clinical-stage specialty ophthalmic biotechnology company announced the interim analysis results from RUBY, the company's Phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis.
  • In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301 was safe and demonstrated an effective, dose-dependent anti-viral response.
  • The company's lead development candidate, OKG-0502, is a fixed dose combination of a broad-spectrum antiviral (OKG-0301) that functions intracellularly to inhibit viral replication and an ocular decongestant that addresses the associated signs and symptoms of adenoviral conjunctivitis.
  • To learn more about the RUBY trial, visit www.rubytrial.com.au or clinicaltrials.gov (NCT03856645).\n"

Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medicine, Clinical research, Articles, Health sciences, Deception, Placebo, Disease, Antiviral drug, ACTIV-2, BRII-196 and BRII-198, ACTIV-2, BRII-196 AND BRII-198

Pre-defined safety and efficacy criteria, including assessments of antiviral activity and clinical efficacy, relative to placebo, were evaluated during this review in ambulatory patients with COVID-19 at high risk for progression to severe disease.

Key Points: 
  • Pre-defined safety and efficacy criteria, including assessments of antiviral activity and clinical efficacy, relative to placebo, were evaluated during this review in ambulatory patients with COVID-19 at high risk for progression to severe disease.
  • Participants identified as being at high risk for progression to more severe disease, are eligible for enrollment onto BRII 196/198 or placebo.
  • Phase 3 evaluation is a continuation of the Phase 2 trial for agents that meet study-defined criteria for further evaluation.
  • Brii Bio is developing treatments for illnesses with significant public health burdens, including infectious diseases and CNS diseases.

Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19

Retrieved on: 
Wednesday, April 28, 2021
Health sciences, Health, Medicine, COVID-19, Occupational safety and health, Public health, Zoonoses, Severe acute respiratory syndrome, Brilacidin, Antiviral drug, COVID-19 drug repurposing research

\xe2\x80\x9cWe are hopeful Brilacidin will emerge not only as an effective COVID-19 therapeutic, but also as a desperately needed broad spectrum antiviral.

Key Points: 
  • \xe2\x80\x9cWe are hopeful Brilacidin will emerge not only as an effective COVID-19 therapeutic, but also as a desperately needed broad spectrum antiviral.
  • We look forward to completing our COVID-19 clinical trial and releasing topline results.\xe2\x80\x9d\nLinked below are recent articles published in the journal Nature.
  • Can drugmakers finally do the right thing?\nInnovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and currently is enrolling patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).
  • Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.

Antiviral Therapeutics Markets, Technologies, & Competitive Landscape Report 2021-2030 Featuring profiles of 195 Companies with 179 Collaborations

Retrieved on: 
Tuesday, April 27, 2021
Antiviral drug, Biocides, SWOT

SWOT (strengths, weaknesses, opportunities and threats) analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent.\nA novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics.

Key Points: 
  • SWOT (strengths, weaknesses, opportunities and threats) analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent.\nA novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics.
  • Various methods for local as well as systemic delivery of antiviral agents and vaccines are described.
  • Antiviral markets are estimated starting with 2020 with projections up to the year 2030.\nProfiles of 195 companies that are involved in developing various technologies and products are profiled and with 179 collaborations.
  • These include major pharmaceutical companies (12), Biopharmaceutical companies with antiviral products (87), Antiviral drug companies (26) as well as viral vaccine companies (71).